|
|
2311 Green Road, Suite A
Ann Arbor, MI 48105 USA
phone:734 302 4000
fax:734 302 9150 |
| Symbol |
Private |
| Founded |
2000 |
| Employees |
|
|
|
| www.nanobio.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Nanotechnology delivery systems for mucosal drug delivery. |
|
| Management |
| James R. Baker, Jr., M.D., Executive Chairman & Chief Scientific Officer; David Peralta, Vice President, Chief Operating & Chief Financial Officer; Mary R. Flack, M.D., Vice President of Clinical & Regulatory Affairs; John Coffey, Vice President of Business Development |
|
|
| |
| Keywords |
| drug delivery, pahrmaceuticals, mucosal, antimicrobial, nanotechnology, flu, infections, vaccines, DrugDelivery |
|
|
|
|
|
| Description |
|
NanoBio Corporation is a privately-held biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, based on its patented NanoStat technology platform.
Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio's lead product candidates target treatments for herpes labialis (cold sores), onychomycosis (nail fungus) and mucosal vaccines for Hepatitis B and Influenza. The company's pipeline also includes products that target genital herpes, herpes zoster (shingles), and methicillin resistant Staphylococcus aureus (MRSA). |
|
| Products / Services |
NanoBio's commercial product pipeline consists of five anti-infective pharmaceuticals and two mucosal vaccines, including Antimicrobial Nanoemulsions, Mucosal Prophylaxis (flu, colds, infections), Mucosal Vaccines, and a Nano-scale Drug Delivery System.
|
|
| Technology / Differentiation |
| The NanoStat platform technology enables both topical anti-infective products as well as a broad range of mucosal vaccines. The technology employs high-energy, oil-in-water emulsions that are manufactured at a size of 150-400 nanometers and are stabilized by surfactants.
The unique aspect of products derived from the company's NanoStat technology is that, unlike currently available therapies, NanoBio's treatments are selectively toxic to microbes while non-irritating to skin and mucous membranes.
The NanoStat technology also enables a platform of nanoemulsion based mucosal vaccines. When either whole virus or a recombinant protein antigen is simply mixed with nanoemulsion and placed on the naso-pharynx, the nanoemulsion serves as a potent adjuvant, producing both mucosal immunity and systemic immune response. Active development programs are underway for Influenza and Hepatitis B. |
|
|
| Status |
| NanoBio is currently conducting a Phase 2b clinical trial with NB-001 for herpes labialis and a Phase 2 trial with NB-002 for the treatment of onychomycosis. These studies are being conducted in numerous clinics throughout the US and Canada. |
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
